The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-20
DOI
10.3389/fimmu.2021.793964
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
- (2021) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of novel biomarkers in Hunner’s interstitial cystitis using the CIBERSORT, an algorithm based on machine learning
- (2021) Kaining Lu et al. BMC Urology
- Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma
- (2021) Kevin T Lynch et al. Journal for ImmunoTherapy of Cancer
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer
- (2020) Kyoko Yamaguchi et al. OncoImmunology
- Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives
- (2020) Yoshiyuki Akiyama et al. INTERNATIONAL JOURNAL OF UROLOGY
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- (2020) Nick van Dijk et al. NATURE MEDICINE
- Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
- (2020) Jianjun Gao et al. NATURE MEDICINE
- Molecular Taxonomy of Interstitial Cystitis/Bladder Pain Syndrome Based on Whole Transcriptome Profiling by Next-Generation RNA Sequencing of Bladder Mucosal Biopsies
- (2019) Yoshiyuki Akiyama et al. JOURNAL OF UROLOGY
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer
- (2019) Alessia Echarti et al. Cancers
- Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer
- (2019) Alfonso Gómez de Liaño Lista et al. EUROPEAN UROLOGY
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
- (2018) Bernadett Szabados et al. EUROPEAN UROLOGY
- Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development
- (2018) David G. Hill et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
- (2018) Nick van Dijk et al. EUROPEAN UROLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Topography of cancer-associated immune cells in human solid tumors
- (2018) Jakob Nikolas Kather et al. eLife
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer
- (2017) Florian Posch et al. OncoImmunology
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
- (2015) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients
- (2015) Stine L Figenschau et al. BMC CANCER
- Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses
- (2015) Nikhil S. Joshi et al. IMMUNITY
- Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome: AUA Guideline Amendment
- (2015) Philip M. Hanno et al. JOURNAL OF UROLOGY
- Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
- (2013) B Goeppert et al. BRITISH JOURNAL OF CANCER
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Lymphoid aggregates in Crohn's colitis and mucosal immunity
- (2013) Carlos A. Rubio et al. VIRCHOWS ARCHIV
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation